23 results about "Thioredoxin" patented technology

A polyclonal antibody composition specifically binds the pTonB epitope (SEQ ID NO: 11) from Acinetobacter baumannii and is elicited by immunization with a multi-epitope antigen comprising thioredoxin leader, rigid linker, and kernels including SEQ ID NOs: 6, 7, 11, 12, and 8. These antibodies enhance opsonophagocytic killing of A. baumannii Ci79 via classical complement activation and Fey receptor-mediated phagocytosis by bone marrow-derived macrophages. Absorption of pTonB-specific antibodies reduces killing by >70%, confirming epitope dominance. Passive transfer of the composition protects >60% of mice in a lethal intranasal challenge model. Pharmaceutical compositions, treatment methods (alone or with antibiotics like colistin), prophylactic uses, diagnostic kits, and polyclonal compositions are disclosed for combating multidrug-resistant A. baumannii infections.

The invention belongs to the technical field of cosmetics, and particularly relates to a cell energy activation composition with an anti-aging effect and a preparation method thereof, the cell energy activation composition with the anti-aging effect and the preparation method thereof are characterized in that the cell energy activation composition with the anti-aging effect comprises the following components: 3-10 parts of thiotaurine and 0.01-0.5 part of a metal ion compound, the composition is prepared from the following raw materials in parts by weight: 0.05-0.5 part of an antioxidant, 0.005-0.05 part of redox regulatory protein, 0.1-6 parts of a raw grass-containing extract, 0.01-1 part of 4-tert-butyl cyclohexanol and 0.05-3 parts of a lipidosome delivery system, according to the invention, multi-channel energy activation is carried out: thiotaurine participates in energy metabolism, metal ions promote enzyme activity, thioredoxin maintains redox balance, and mitochondrial functions are comprehensively improved; liposomal delivery enhances absorption: the transdermal ability of active matters is improved, the stability is enhanced, and the utilization rate is increased; multiple anti-aging mechanisms are as follows: oxidation resistance, saccharification resistance and cell repair.

This invention relates to the field of gene editing, and in particular to a very small CRISPR / Cas12hacker gene cutting system. The CRISPR / Cas12 gene cutting system includes a Cas12hacker nuclease or a polynucleotide encoding the Cas12hacker nuclease, and also includes guide RNA or a polynucleotide encoding the guide RNA. By binding to the host factor thioredoxin TrxA, the CRISPR-Cas12 gene cutting system enhances the efficiency of the Cas12hacker nuclease in precisely cutting double-stranded DNA, thereby achieving genomic DNA double-strand breaks and highly efficient in vitro DNA double-strand cutting.

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to bacteriophage-tolerant escherichia coli and application of the bacteriophage-tolerant escherichia coli in the field of L-tryptophan synthesis. Specifically, the escherichia coli is obtained at least by knocking out a trxA gene for coding thioredoxin in an original strain, carrying out site-specific modification on FhuA protein, and knocking out a trpR gene for coding L-tryptophan operon repressor protein and a tnaA gene for coding tryptophan enzyme. Genetic engineering modification is performed on wild escherichia coli based on a genetic engineering technology, so that the escherichia coli genetically engineered bacterium tolerant to the bacteriophage is finally obtained, and meanwhile, the utilization rate of glucose can be remarkably improved, so that the L-tryptophan synthesis level is relatively high, and the application prospect is wide. And the method can be expanded and applied to microbial fermentation of other various high-added-value compounds, so that the method has a good practical application value.

The invention relates to methods of inhibiting hair growth in a subject, the method comprises administering an inhibitor of lactic acid fermentation to the subject, wherein the inhibitor is selected from the group consisting of pyruvate dehydrogenase kinase inhibitor, desoxyrhapontigenin, a phosphofructokinases inhibitor, a thioredoxin-1 inhibitor, L- Asparaginase, a GLUT1 inhibitor, a glutaminase C inhibitor, a hexokinase inhibitor and an mTORCI and mTORC2 inhibitor. Also provided herein are compositions for inhibiting hair growth and methods of screening for inhibitors of hair growth.

The application belongs to the technical field of genetic engineering. The application provides application of a thiol-oxidoreductase in promoting keratin enzymolysis and a method for promoting keratin enzymolysis. The thiol-oxidoreductase is applied to a keratin enzymolysis system, and the enzymolysis effect is obviously improved. Through testing, the enzymolysis effect of the thiol-oxidoreductase combined with a protease on keratin is not only obviously higher than the enzymolysis effect of a single protease, but also is better than the hydrolysis of keratin by a chemical reducing agent with the same concentration. The application retains the advantages of enzyme method "green chemistry" and is friendly to the environment.

This invention discloses a compound seed treatment agent containing metalaxyl-M and tebuconazole, its preparation method, and its uses, belonging to the technical field of seed treatment agents. The suspension of this invention uses metalaxyl-M, tebuconazole, and sodium selenite as the main components, supplemented with emulsifying and dispersing agents, wetting and dispersing agents, antifreeze agents, suspending agents, film-forming agents, and warning colors, and is prepared by adding deionized water to a sufficient volume. Metalaxyl-M targets and inhibits ribosomal RNA polymerase I of oomycete pathogens, while tebuconazole targets and inhibits sterol 14α-demethylase. The two have complementary fungicidal spectra, synergistically controlling maize stalk rot and maize head smut. Sodium selenite, by inhibiting the oxidative stress defense system of pathogenic fungi involving glutathione and thioredoxin, promotes the effects of the two main components and simultaneously remediates selenium-deficient soils. This invention is suitable for the green and efficient control of maize stalk rot and head smut, and also has the function of ecological restoration of selenium-deficient soils.

The invention relates to a piperidine derivative as shown in a formula (I), and an isotope form, a stereoisomer, a tautomer, a cis-trans-isomer, pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a hydrate, a prodrug and a polymorphic substance of the piperidine derivative. The compound has a good application prospect in the aspect of preparing medicines for preventing and / or treating TXNIP activity mediated diseases.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX) engineered to synthesize DNA with reduced stutter artifacts in the absence of a reducing agent. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein and methods of use thereof in the absence of a reducing agent are also within the scope herein.

The invention belongs to the field of biotechnology and medicine, provides application of thioredoxin TXN1 and TRP14 as a bidirectional switch for regulating and controlling a cell death mode and application of an anti-cancer drug, and particularly relates to new application of TXN1 and TRP14. The invention reveals that TXN1 and TRP14 play a role of a bidirectional regulation switch in regulating the sensitivity of non-small cell lung cancer cells to different programmed death modes (including apoptosis, ferroptosis and disulfide death) for the first time. By reducing the activity or expression of TXN1 or TRP14, the sensitivity of cancer cells to apoptosis inducers and ferroptosis inducers can be enhanced, but the resistance of the cancer cells to glucose deprivation-induced disulfide death is remarkably enhanced. The discovery shows that inhibition of TXN1 / TRP14 can be combined with an apoptosis / ferroptosis inducer to treat cancers; meanwhile, an inhibitor aiming at TXN1 / TRP14 can be used for preventing or treating diseases related to disulfide death. The invention provides a cancer treatment composition based on the discovery, a drug screening method and biomarker application.

This invention discloses the application of a rubber tree thioredoxin or related biomaterials, belonging to the field of biotechnology, for improving the resistance of rubber trees to low temperature and oxidative stress at the molecular level. The amino acid sequence of thioredoxin is shown in SEQ ID NO. 5. Experiments have shown that expression of the gene encoding this thioredoxin in yeast enhances the cold resistance and antioxidant capacity of recombinant yeast. Therefore, the gene encoding this thioredoxin can be used to improve the cold resistance and antioxidant capacity of plants or microorganisms.

The invention discloses an antibody for resisting thioredoxin, and relates to the field of antibodies. The anti-thioredoxin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, can be specifically bound with thioredoxin, has good binding activity and stability, and is wide in application and good in application prospect.

The application discloses a combined drug for treating prostate cancer and application, the combined drug is a combined drug of FEN1-IN-4 and TRi-1 administered respectively or simultaneously, the FEN1-IN-4 is an inhibitor targeting Flap endonuclease 1, and the TRi-1 is an inhibitor targeting thioredoxin (TXN) antioxidant system.The combined treatment scheme of FEN1-IN-4 and TRi-1 provided by the application firstly shows a strong antitumor effect superior to single drug in vitro experiment.FEN1-IN-4 as FEN1 specific inhibitor can block the endonuclease function of FEN1 by combining with the active site of FEN1, and can achieve significant growth inhibition to various prostate cancer cell lines such as LNCaP, 22RV-1, PC3, DU145, and the like, and TRi-1 as TXN antioxidant system inhibitor can target to destroy the oxidative stress balance of tumor cells, and the two act on different key pathways (DNA replication / damage repair pathway and antioxidant defense pathway) of tumor cells, forming a "double targeting" synergistic effect.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX) engineered to synthesize DNA with reduced stutter artifacts in the absence of a reducing agent. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein and methods of use thereof in the absence of a reducing agent are also within the scope herein.

Methods for treating and / or preventing Alzheimer's disease via administration of thioredoxin-1 (Trx1) mRNA- or miR-551b miR-NA-containing exosomes derived from Flk-1+ vascular endothelial progenitor cells are reported. Further, wherein the subject carries the APOE E4 risk factor gene; wherein the subject also has mild cognitive impairment (MCI); and wherein the Flk-1+ exosomes are derived from vascular endothelial progenitor cells or the exosomes are derived from neural stem cells.

The present application relates to a kind of molecular chaperone, nano-carrier and its preparation method and application.The molecular chaperone is the recombinant histidine-sulphur oxygen protein coupled with single-stranded DNA, and the cysteine residue is introduced in the protein and coupled with the single-stranded DNA of amino modification.The nano-carrier is DNA tetrahedron, and the DNA tetrahedron is obtained by self-assembly based on base pairing principle from multiple DNA single strands.DNA nano-carrier is used to deliver the molecular chaperone, can realize HTrX to specific subcellular compartment, i.e.the targeted delivery of ribosome, so that the protein in ribosome exerts biological effect, reduces the negative influence of oxidative stress on protein synthesis to reverse the aging process.The present application also discloses the application of the above-mentioned molecular chaperone and nano-carrier in preparing anti-aging drugs.

The invention provides a mu-conopeptide fusion protein and a preparation method of mu-conopeptide, and belongs to the technical field of biology. The invention provides a [mu]-conopeptide fusion protein. The [mu]-conopeptide fusion protein comprises a folded protein in a connected state and [mu]-conopeptide which is repeatedly connected in series, the folded protein comprises thioredoxin and disulfide bond isomerase; the amino acid sequence of the mu-conopeptide is as shown in SEQ ID NO: 1. According to the method disclosed by the invention, the thioredoxin and the disulfide bond isomerase are used as folding proteins, so that the tandem expressed mu-conopeptide can correctly and effectively form the mu-conopeptide with three pairs of disulfide bonds, and the method can effectively improve the yield of the mu-conopeptide. In addition, the [mu]-conopeptide fusion protein can be used for biosynthesizing [mu]-conopeptide, and compared with a traditional method, the [mu]-conopeptide fusion protein is more environmentally friendly, lower in cost compared with solid-phase synthesis and suitable for large-scale production.

Provided herein are compositions and systems comprising a DNA polymerase domain, a thioredoxin binding domain (TBD), and thioredoxin (TRX), wherein one or both of the TRX and TBD are fused or otherwise conjugated to the DNA polymerase domain. The TRX or TBD may also be provided as separate entities (e.g., binary systems) in the systems herein. The DNA polymerase / TBD / TRX compositions and systems herein are engineered to reduce stutter and / or produce fewer stutter artifacts. Kits comprising the DNA polymerase / TBD / TRX compositions and systems herein, and methods for using the same, are also within the scope of the present specification.

To provide a cosmetic having enhanced elastin expression-promoting effect of thioredoxin, and to provide a new elastin expression-promoting agent.SOLUTION: The cosmetic contains an Albizia julibrissin bark extract and thioredoxin, and the dermal elastin expression promoter contains the Albizia julibrissin bark extract.SELECTED DRAWING: Figure 3

Disclosed are compositions and methods for decreasing the viscosity and / or cohesiveness of and / or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.

The present invention aims to provide a novel fusion protein that can be used in treating adipose-related diseases. [Solution] The present invention provides a fusion protein comprising fibroblast growth factor 21 (FGF21), thioredoxin (Trx), and serum albumin (SA), wherein the FGF21 is FGF21 that does not contain a signal sequence.

The subject of this invention is a construct of an expression vector for expressing recombinant µ-conotoxin TIIIA or TIIIAlaMut, characterized in that it comprises the nucleotide sequence of µ-conotoxin TIIIA SEQ ID NO:1 or the nucleotide sequence of µ-conotoxin TIIIAlaMut SEQ ID NO:4, both sequences containing a sequence encoding six histidine residues (6His) at the 5' end, which is linked via a serine-glycine-serine linker (SGS) to a construct encoding a TRX::TIIIA fusion protein or a TRX::TIIIAlaMut fusion protein, wherein the TRX::TIIIA fusion protein comprises the µ-conotoxin TIIIA gene and a gene encoding a leader protein, and the TRX::TIIIAlaMut fusion protein comprises the µ-conotoxin TIIIAlaMut gene and a leader protein, wherein the leader protein is a thioredoxin (TRX) modified by site-directed mutagenesis, wherein the amino acid methionine at position 37 is replaced by lysine. Another subject of the invention is an expression vector comprising a construct according to the invention under the control of a constitutive promoter. Another subject of the invention is isolated *E. coli* cells comprising an expression vector according to the invention. Another subject of the invention is a method for producing µ-conotoxin TIIIA or TIIIAlaMut in *E. coli* using an expression vector comprising a construct according to the invention, characterized in that the method comprises the steps of: a) transforming *E. coli* cells with an expression vector comprising a construct according to the invention under the control of a constitutive promoter, said expression vector encoding a TRX::TIIIA fusion protein having the amino acid sequence SEQ ID NO:2 or having SEQ ID NO:2. a) TRX::TIIIAlaMut fusion protein NO:5; b) Expression of the TRX::TIIIA or TRX::TIIIAlaMut fusion protein; c) Isolation and purification of the TRX::TIIIA or TRX::TIIIAlaMut fusion protein; d) Formation of disulfide bonds by glutathione treatment of the purified TRX::TIIIA or TRX::TIIIAlaMut fusion protein in GSH / GSSG and dialyzing in buffer; e) Cleavage of the TRX::TIIIA or TRX::TIIIAlaMut fusion protein with the formed disulfide bonds by cyanogen bromide; f) Purification of the cleaved TIIIA or TIIIAlaMut peptide.

The application belongs to the technical field of biotechnology, and particularly relates to a mutant of thioredoxin as well as a preparation method and application thereof. The mutant with high antioxidant activity is obtained by combining mutation on wild-type thioredoxin. The mutant has the advantages of high expression, good solubility, strong antioxidant activity and anti-inflammatory soothing effect. The mutant can be combined with other raw and auxiliary materials, and can be applied to skin care and washing and caring products, and is a new efficient active raw material.